SMARCA2 and lung carcinoma: Recently, two insertion/deletion (indel) polymorphisms have newly identified in the promoter region (−1321 bp and −741 bp upstream of the BRM transcription start site, i.e. rs3832613 and rs34480940) of BRM and have been proved to be associated with loss of BRM expression and lung cancer risk [13].